FDA approves first antagonist for adult major depressive disorder
ADC评论
August 20, 2022
On August 19, Axsome Therapeutics announced that the US FDA approved Auvelity (dextromethorphan 45mg + bupropion 105mg) compound sustained-release tablets for the treatment of adult
